Thymosin β4 Is an Endogenous Iron Chelator and Molecular Switcher of Ferroptosis

Thymosin β4 (Tβ4) was extracted forty years agofrom calf thymus. Since then, it has been identified as a G-actin binding protein involved in blood clotting, tissue regeneration, angiogenesis, and anti-inflammatory processes. Tβ4 has also been implicated in tumor metastasis and neurodegeneration. However, the precise roles and mechanism(s) of action of Tβ4 in these processes remain largely unknown, with the binding of the G-actin protein being insufficient to explain these multi-actions. Here we identify for the first time the important role of Tβ4 mechanism in ferroptosis, an iron-dependent form of cell death, which leads to neurodegeneration and somehow protects cancer cells against cell death. Specifically, we demonstrate four iron2+ and iron3+ binding regions along the peptide and show that the presence of Tβ4 in cell growing medium inhibits erastin and glutamate-induced ferroptosis in the macrophage cell line. Moreover, Tβ4 increases the expression of oxidative stress-related genes, namely BAX, hem oxygenase-1, heat shock protein 70 and thioredoxin reductase 1, which are downregulated during ferroptosis. We state the hypothesis that Tβ4 is an endogenous iron chelator and take part in iron homeostasis in the ferroptosis process. We discuss the literature data of parallel involvement of Tβ4 and ferroptosis in different human pathologies, mainly cancer and neurodegeneration. Our findings confronted with literature data show that controlled Tβ4 release could command on/off switching of ferroptosis and may provide novel therapeutic opportunities in cancer and tissue degeneration pathologies.

A Semianalytic Afterglow with Thermal Electrons and Synchrotron Self-Compton Emission

We extend previous work on gamma-ray burst afterglows involving hot thermal electrons at the base of a shock-accelerated tail. Using a physically motivated electron distribution based on first-principles simulations, we compute the broadband emission from radio to TeV gamma rays. For the first time, we present the effects of a thermal distribution of electrons on synchrotron self-Compton emission. The presence of thermal electrons causes temporal and spectral structure across the entire observable afterglow, which is substantively different from models that assume a pure power-law distribution for the electrons. We show that early-time TeV emission is enhanced by more than an order of magnitude for our fiducial parameters, with a time-varying spectral index that does not occur for a pure power law of electrons. We further show that the X-ray closure relations take a very different, also time-dependent, form when thermal electrons are present; the shape traced out by the X-ray afterglows is a qualitative match to observations of the traditional decay phase.

BDNF-induced BDNF release mediates presynaptic LTP and is regulated by cannabinoids

Although brain-derived neurotrophic factor (BDNF) and its effector, Tropomyosin receptor kinase B (TrkB), are implicated in activity-dependent synaptic plasticity, the precise underlying mechanisms remain unclear. In the dentate gyrus, a hippocampal input region that expresses uniquely high levels of BDNF, repetitive activation of mossy cells (MCs) induces a presynaptic, BDNF/TrkB-dependent form of LTP at MC to granule cell (GC) synapses. Here, we report that activity-induced BDNF release from MC axons in mice elicits postsynaptic BDNF release in a TrkB- and calcium-dependent manner, and that BDNF-induced BDNF release is essential for LTP induction. Suppression of BDNF release by tonic and phasic activity of presynaptic type-1 cannabinoid receptors dampened LTP, revealing an unprecedented role of these receptors in controlling neuropeptide release. Lastly, BDNF-mediated MC-GC LTP can be elicited in vivo. Thus, BDNF-induced BDNF release emerges as a mechanism for activity-dependent LTP that may contribute to dentate gyrus-dependent learning, epilepsy, and neuropsychiatric disorders.

Ferroptosis-Inducing Nanomedicine for Cancer Therapy

Ferroptosis, a new iron- and reactive oxygen species–dependent form of regulated cell death, has attracted much attention in the therapy of various types of tumors. With the development of nanomaterials, more and more evidence shows the potential of ferroptosis combined with nanomaterials for cancer therapy. Recently, there has been much effort to develop ferroptosis-inducing nanomedicine, specially combined with the conventional or emerging therapy. Therefore, it is necessary to outline the previous work on ferroptosis-inducing nanomedicine and clarify directions for improvement and application to cancer therapy in the future. In this review, we will comprehensively focus on the strategies of cancer therapy based on ferroptosis-inducing nanomedicine currently, elaborate on the design ideas of synthesis, analyze the advantages and limitations, and finally look forward to the future perspective on the emerging field.

Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia

The thalassemias are inherited quantitative disorders of hemoglobin synthesis with a significant worldwide burden, which result in a wide spectrum of disease from the most severe transfusion-dependent form to the mildest asymptomatic carrier state. In this article, we discuss the importance of carrier, prenatal, and newborn screening for thalassemia. We examine the rationale for who should be screened and when, as well as the current methodology for screening. Deficiencies in the newborn screening program are highlighted as well. With the advent of inexpensive and rapid genetic testing, this may be the most practical method of screening in the future, and we review the implications of population-based implementation of this strategy. Finally, a case-based overview of the approach for individuals with the trait as well as prospective parents who have a potential fetal risk of the disease is outlined.

Roles of ferroptosis in urologic malignancies

Ferroptosis, an iron-dependent form of non-apoptotic cell death, is believed to strongly contribute to the pathogenesis of multiple cancers. Recently, the positive association between ferroptosis and urologic malignancies has drawn considerable attention, while a comprehensive review focused on this issue is absent. Based on this review, ferroptosis has been implicated in the development and therapeutic responses of prostate cancer, kidney cancer, and bladder cancer. Mechanistically, a large number of biomolecules and tumor-associated signaling pathways, including DECR1, PANX2, HSPB1, ACOT8, SUV39H1, NCOA4, PI3K-AKT-mTOR signaling, VHL/HIF-2α pathway, and Hippo/TAZ signaling pathway, have been reported to regulate ferroptosis in urologic cancers. Ferroptosis inducers, such as erastin, ART, CPNPs, and quinazolinyl-arylurea derivatives, exert potential therapeutic effects per se and/or enhance the anticancer response of other anticancer drugs in urologic oncology. A better understanding of ferroptosis may provide a promising way to treat therapy-resistant urologic cancers.

C-ferroptosis is an iron-dependent form of regulated cell death in cyanobacteria

Ferroptosis is an oxidative and iron-dependent form of regulated cell death (RCD) recently described in eukaryotic organisms like animals, plants, and parasites. Here, we report that a similar process takes place in the photosynthetic prokaryote Synechocystis sp. PCC 6803 in response to heat stress. After a heat shock, Synechocystis sp. PCC 6803 cells undergo a cell death pathway that can be suppressed by the canonical ferroptosis inhibitors, CPX, vitamin E, Fer-1, liproxstatin-1, glutathione (GSH), or ascorbic acid (AsA). Moreover, as described for eukaryotic ferroptosis, this pathway is characterized by an early depletion of the antioxidants GSH and AsA, and by lipid peroxidation. These results indicate that all of the hallmarks described for eukaryotic ferroptosis are conserved in photosynthetic prokaryotes and suggest that ferroptosis might be an ancient cell death program.

Biomimetic Nanomaterials Triggered Ferroptosis for Cancer Theranostics

Ferroptosis, as a recently discovered non-apoptotic programmed cell death with an iron-dependent form, has attracted great attention in the field of cancer nanomedicine. However, many ferroptosis-related nano-inducers encountered unexpected limitations such as immune exposure, low circulation time, and ineffective tumor targeting. Biomimetic nanomaterials possess some unique physicochemical properties which can achieve immune escape and effective tumor targeting. Especially, certain components of biomimetic nanomaterials can further enhance ferroptosis. Therefore, this review will provide a comprehensive overview on recent developments of biomimetic nanomaterials in ferroptosis-related cancer nanomedicine. First, the definition and character of ferroptosis and its current applications associated with chemotherapy, radiotherapy, and immunotherapy for enhancing cancer theranostics were briefly discussed. Subsequently, the advantages and limitations of some representative biomimetic nanomedicines, including biomembranes, proteins, amino acids, polyunsaturated fatty acids, and biomineralization-based ferroptosis nano-inducers, were further spotlighted. This review would therefore help the spectrum of advanced and novice researchers who are interested in this area to quickly zoom in the essential information and glean some provoking ideas to advance this subfield in cancer nanomedicine.

The role of ferroptosis in organ toxicity

Ferroptosis, an iron-dependent form of programmed cell death, is characterized by iron overload, increased reactive oxygen species (ROS) generation, and depletion of glutathione (GSH) and lipid peroxidation. Lipophilic antioxidants and iron chelators can prevent ferroptosis. GSH-dependent glutathione peroxidase 4 (GPX4) prevents lipid ROS accumulation. Ferroptosis is thought to be initiated through GPX4 inactivation. Moreover, mitochondrial iron overload derived from the degradation of ferritin is involved in increasing ROS generation. Ferroptosis has been suggested to explain the mechanism of action of organ toxicity induced by several drugs and chemicals. Inhibition of ferroptosis may provide novel therapeutic opportunities for treatment and even prevention of such organ toxicities.

Improved treatment of dark matter capture in neutron stars III: nucleon and exotic targets

We consider the capture of dark matter (DM) in neutron stars via scattering on hadronic targets, including neutrons, protons and hyperons. We extend previous analyses by including momentum dependent form factors, which account for hadronic structure, and incorporating the effect of baryon strong interactions in the dense neutron star interior, rather than modelling the baryons as a free Fermi gas. The combination of these effects suppresses the DM capture rate over a wide mass range, thus increasing the cross section for which the capture rate saturates the geometric limit. In addition, variation in the capture rate associated with the choice of neutron star equation of state is reduced. For proton targets, the use of the interacting baryon approach to obtain the correct Fermi energy is essential for an accurate evaluation of the capture rate in the Pauli-blocked regime. For heavy neutron stars, which are expected to contain exotic matter, we identify cases where DM scattering on hyperons contributes significantly to the total capture rate. Despite smaller neutron star capture rates, compared to existing analyses, we find that the projected DM-nucleon scattering sensitivity greatly exceeds that of nuclear recoil experiments for a wide DM mass range.